Clinical Trial Update: Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LEGALON SIL for preventing Hepatitis C recurrence in stable liver transplant recipients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Legalon SIL (silibinin)

Snippet

Sponsor: Rottapharm | Conditions: Hepatitis C Virus Recurrence | Phase 2 | Status: TERMINATED